- Home
- ADVM vs MNOV Comparison
ADVM vs MNOV Comparison
Compare ADVM & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADVM | MNOV |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 76.0M |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ADVM | MNOV |
|---|---|---|
| Price | $4.16 | $1.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $11.60 | $7.00 |
| AVG Volume (30 Days) | ★ 372.0K | 193.2K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $257,917.00 |
| Revenue This Year | $1,191.10 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.78 | $1.13 |
| 52 Week High | $6.98 | $2.48 |
Technical Indicators
Market Signals| Indicator | ADVM | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 53.44 |
| Support Level | $4.07 | $1.41 |
| Resistance Level | $4.23 | $1.63 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 50.31 | 28.26 |
Price Performance
Historical ComparisonAbout ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.